SPRO
Spero Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.02 / 10
Outperform
Fund flow analysis reveals a score of 7.02/10, indicating robust capital inflow despite negative trends in block, small, medium, large, and extra-large patterns. The overall fund flow trajectory is positive, providing momentum that partially offsets technical and revenue-related weaknesses. No analyst coverage data is available for SPRO.
Fund Flow Rating
Is money flowing into or out of SPRO?
- SPRO holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.02/10 (Outperform).
